With the completion of this pivotal phase, Musculoskeletal Transplant Foundation (MTF) has successfully delivered to Orthofix a conclusive data package meeting the specifications provided by Orthofix under the parties’ development agreement. The full commercialization of this tissue form, called Trinity Evolution, is ahead of schedule and is now expected by June 2009.
The terms of the development agreement between Orthofix and MTF established a milestone-based program, funded by Orthofix, which calls for MTF to complete the development of a stem cell based bone growth matrix designed to behave like an autograft in spinal and orthopedic surgeries.
The achievement of this pivotal milestone marks the completion of the most substantial part of the development agreement. MTF will now focus on the production of the allograft. Orthofix has exclusive global marketing rights for the new allograft.
Alan Milinazzo, president and CEO of Orthofix International, said: “With the completion of this major developmental milestone, we expect to make this novel stem cell-based tissue form available to surgeons and patients ahead of schedule.”